ESMO肺癌免疫治疗研究进展医学幻灯片课件.pptxVIP

;2016ESMO肺癌免疫治疗研究进展;KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%;晚期NSCLC治疗模式;KEYNOTE-010: PD-L1表达水平与Pembrolizumab治疗晚期NSCLC的OS获益密切相关;PD-L1表达与Pembrolizumab;KEYNOTE-024 研究设计;KEYNOTE-024 研究设计：评价系统;KEYNOTE-024 研究设计：统计学假设;患者流;患者基线特征;M Reck, et al. ESMO 2016 Abstract LBA8;ORR;PFS亚组分析;药物暴露与安全性总结;治疗相关不良事件(10%);Pembrolizumab的免疫介导的不良事件;总结;结论;Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort